Receiving care in a multidisciplinary prostate cancer clinic increases discussion about treatment options and adherence to national guidelines
Newly diagnosed prostate cancer patients have multiple standard-of-care treatment options available, but many are not fully informed of their choices. A study led by researchers at The University of Texas MD Anderson Cancer Center found men who seek treatment at a multidisciplinary (MultiD) prostate cancer clinic are more likely to be advised about treatment choices and to receive care that complies with evidence-based treatment guidelines...
San Antonio luncheon to honor former U.S. Sec. of State Rex Tillerson
The University of Texas MD Anderson Cancer Center marks the 10th year of A Conversation With a Living Legend® in San Antonio with a luncheon...
Prostate cancer bone metastases thwart immunotherapy by producing TGF-β
Prostate cancer that spreads to the bone triggers the destruction of bone tissue that, in turn, thwarts the effectiveness of immune checkpoint...
Study shows secondary surgery does not improve overall survival for recurrent ovarian cancer patients
Researchers from The University of Texas MD Anderson Cancer Center reported that secondary tumor-reduction, or cytoreduction, surgery followed by chemotherapy did not result in longer survival than chemotherapy alone in patients with platinum-sensitive recurrent ovarian cancer.
The Phase III Gynecologic Oncology Group (GOG)-0213 trial results were published today in the New England Journal of Medicine. Early results from...
Kim Carstens receives Brown Foundation Award for Excellence in Oncology Nursing
Kim Carstens, B.S.N., R.N., O.C.N., is the recipient of the 2019 Brown Foundation Award for Excellence in Oncology Nursing at The University...
MD Anderson, Artios Pharma and ShangPharma announce in-licensing agreement for DNA damage response inhibitor
The University of Texas MD Anderson Cancer Center, Artios Pharma Limited and ShangPharma Innovation today announce the in-licensing by Artios...
MD Anderson and Takeda Announce Collaboration to Accelerate the Development of Clinical-Stage, Off-The-Shelf CAR NK-Cell Therapy Platform
The University of Texas MD Anderson Cancer Center and Takeda Pharmaceutical Company Limited today announced an exclusive license agreement...
MD Anderson statement regarding an assessment by the Centers for Medicare and Medicaid Services
For nearly 80 years, The University of Texas MD Anderson Cancer Center has been a global leader in the fight to end cancer. Our patients trust...